Biomedtech News
Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
Abivax's drug-candidate ABX196, shows good tolerability and promising signals of clinical benefit in liver cancer
ABX464 shows excellent long-term efficacy data in Abivax's phase 2B maintenance trial in ulcerative colitis
Abivax presents first-half 2021 financial results and operations update
Abivax provides an update on the ABX464 clinical data and development strategy in ulcerative colitis
Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway
Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck
Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out
Abivax receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis
